Edition:
United States

Aratana Therapeutics Inc (PETX.OQ)

PETX.OQ on NASDAQ Stock Exchange Global Market

5.17USD
28 Mar 2017
Change (% chg)

-- (--)
Prev Close
$5.17
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
145,454
52-wk High
$10.71
52-wk Low
$4.86

Latest Key Developments (Source: Significant Developments)

Aratana Therapeutics posts Q4 loss per share $0.64
Monday, 13 Mar 2017 04:26pm EDT 

Aratana Therapeutics Inc : Aratana Therapeutics reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.64 . Q4 revenue $292,000 .Aratana Therapeutics Inc - expects cash, cash equivalents and short-term investments will fund operations and debt obligations through March 31, 2018.  Full Article

Aratana therapeutics anticipates that Entyce will be commercially available by late-2017
Monday, 6 Feb 2017 08:09am EST 

Aratana Therapeutics Inc : Anticipates that Entyce will be commercially available by late-2017 . Also conducting additional clinical work in other surgical procedures to potentially expand label for Nocita in dogs . Received response from FDA in connection with post-approval supplement request to transfer manufacturing of Entyce to new vendor .FDA has requested additional information regarding proposed transfer.  Full Article

Aratana Therapeutics reports Q3 financial results
Thursday, 3 Nov 2016 05:00pm EDT 

Aratana Therapeutics Inc : Continues to anticipate commercial launch of ENTYCE in Q1 of 2017 . Aratana Therapeutics reports third quarter 2016 financial results .Q3 loss per share $0.38.  Full Article

Aratana Therapeutics granted FDA approval of Nocita
Monday, 15 Aug 2016 04:30pm EDT 

Aratana Therapeutics Inc : Aratana Therapeutics granted FDA approval of Nocita® (bupivacaine liposome injectable suspension) .Anticipates Nocita will be commercially available to veterinarians in fall of 2016.  Full Article

Aratana posts Q2 EPS $0.61
Thursday, 4 Aug 2016 04:20pm EDT 

Aratana Therapeutics Inc : Q2 earnings per share $0.61 . Aratana therapeutics reports second quarter 2016 financial results .Q2 revenue $38 million versus $45 million.  Full Article

Aratana Therapeutics posts Q2 earnings per share $0.61
Thursday, 4 Aug 2016 04:20pm EDT 

Aratana Therapeutics Inc : Q2 revenue $38 million versus $230,000 . Aratana Therapeutics reports second quarter 2016 financial results .Q2 earnings per share $0.61.  Full Article

Aratana Therapeutics files for FDA approval of Nocita
Thursday, 30 Jun 2016 09:00am EDT 

Aratana Therapeutics Inc : Aratana Therapeutics files for FDA approval of Nocita(bupivacaine liposome injectable suspension) . Says animal drug user fee act (ADUFA) date for approval is August 28, 2016 . Aratana anticipates Nocita will be commercially available to veterinarians in fall of 2016 .Says anticipates Nocita will be commercially available to veterinarians in fall of 2016.  Full Article

Aratana Therapeutics receives CMC technical section complete letter
Thursday, 2 Jun 2016 09:23am EDT 

Aratana Therapeutics Inc : Received a technical section complete letter for chemistry, manufacturing and controls for nocita . Aratana Therapeutics receives CMC technical section complete letter for post-operative pain therapeutic .If nocita receives FDA approval, aratana expects to commence commercialization in late-2016.  Full Article

Aratana Therapeutics says FDA approved its drug for appetite stimulation in dogs
Tuesday, 17 May 2016 06:00pm EDT 

Aratana Therapeutics Inc : Intends to commercially launch Entyce in conjunction with North American Veterinary Conference in February 2017 .Aratana Therapeutics granted FDA approval of Entyce® (capromorelin oral solution).  Full Article

Aratana Therapeutics Inc, Elanco announce strategic collaboration
Monday, 25 Apr 2016 04:05am EDT 

Aratana Therapeutics Inc:Aratana, Elanco announce global strategic collaboration.Elanco has licensed animal health rights to Aratana's Galliprant.Agreement grants Elanco exclusive rights to develop, manufacture, market, and commercialize Galliprant globally.Agreement grants Elanco exclusive rights to co-promote product with aratana in united states.Under terms of agreement, Aratana will receive an upfront payment of $45 million.Aratana Therapeutics says will receive additional payments upon achievement of certain development, regulatory and sales milestones up to $83 million.  Full Article

More From Around the Web

BRIEF-Aratana Therapeutics posts Q4 loss per share $0.64

* Aratana Therapeutics reports fourth quarter and full year 2016 financial results